Differential [qlco]
effects [qlco]
Oral [spco]
Conjugated estrogen [horm, phsu, strd]
Equine [mamm]
Transdermal [ftcn]
Estrogen [horm, phsu, strd]
atherosclerotic vascular disease [dsyn]
Markers, Risk [qlco]
Endothelial [tisu]
function [phsf]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Revealed [qlco]
HRT [topp]
atherosclerotic vascular disease [dsyn]
Methods [inpr]
investigated [ftcn]
effects [qlco]
HRT [topp]
Administration [ocac]
ROUTE [ftcn]
Marker [clna]
atherosclerotic vascular disease [dsyn]
Endothelial [tisu]
function [phsf]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Oral [spco]
HRT [topp]
Group [idcn]
N NOS [aapp, imft]
Received [qlco]
Conjugated estrogen [horm, phsu, strd]
Equine [mamm]
mg day [qnco]
Transdermal [ftcn]
HRT [topp]
Group [idcn]
N NOS [aapp, imft]
Received [qlco]
17 beta-Estradiol [horm, phsu, strd]
Gel [bodm]
mg day [qnco]
months [tmco]
Control Group [grup]
N 30 [orch, phsu]
treatment [ftcn]
months [tmco]
C-reactive protein [aapp, imft]
Rose [plnt]
mg dl [qnco]
P NOS [aapp, imft]
Oral [spco]
HRT [topp]
Group [idcn]
Unchanged [fndg]
Transdermal [ftcn]
HRT [topp]
Control Groups [grup]
Flow [npop]
mediated [socb]
Vasodilation [phsf]
FMD [cgab, dsyn]
Brachial Artery [bpoc]
Increased [qnco]
HRT [topp]
Oral [spco]
HRT [topp]
14 7 [qnco]
Oral [spco]
HRT [topp]
P NOS [aapp, imft]
Transdermal [ftcn]
HRT [topp]
Transdermal [ftcn]
HRT [topp]
P NOS [aapp, imft]
Conclusions [idcn]
Suggest [idcn]
Oral [spco]
Estrogen [horm, phsu, strd]
atherosclerotic vascular disease [dsyn]
Increasing [ftcn]
Acute inflammation [fndg]
transdermal estrogen [horm, phsu, strd]
transdermal estrogen [horm, phsu, strd]
exert [orgf]
Endothelial [tisu]
function [phsf]
Oral [spco]
Estrogen [horm, phsu, strd]
Transdermal route [ftcn]
Favorable [qlco]
atherosclerotic vascular disease [dsyn]
Risks [qlco]
